A5057832944- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Cytomegalovirus and herpesvirus research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Polyomavirus and related diseases
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Immune cells in cancer
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Renal Transplantation Outcomes and Treatments
- Herpesvirus Infections and Treatments
- Cell Adhesion Molecules Research
- Neutropenia and Cancer Infections
- Phagocytosis and Immune Regulation
- Antifungal resistance and susceptibility
- Biomedical Ethics and Regulation
- Chronic Myeloid Leukemia Treatments
- Virus-based gene therapy research
- Mycobacterium research and diagnosis
- Immunodeficiency and Autoimmune Disorders
- Nanoplatforms for cancer theranostics
- interferon and immune responses
- Multiple Myeloma Research and Treatments
University of California, San Francisco
1996-2025
UCSF Helen Diller Family Comprehensive Cancer Center
2023-2025
University of Miami
2015-2024
Sylvester Comprehensive Cancer Center
2014-2023
City College of San Francisco
2023
University of Miami Health System
2017-2022
Varian Medical Systems (United States)
2022
Roche (Switzerland)
2021
University of Miami Hospital
2018-2020
Cellular Therapeutics (United Kingdom)
2019
In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.In this multicenter, 2 we enrolled 111 diffuse lymphoma, primary mediastinal or transformed follicular who had disease despite undergoing recommended prior therapy. Patients received target dose 2×106 CAR T cells per kilogram body weight receiving conditioning...
Abstract BACKGROUND: Recurrence is a major cause of treatment failure after allogeneic transplantation for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), options are very limited. Azacitidine DNA methyltransferase inhibitor with activity in myeloid disease. The authors hypothesized that low‐dose azacitidine administered transplant would reduce recurrence rates, conducted study to determine safe dose/schedule combination. METHODS: Forty‐five high‐risk patients were...
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant numbers of patients with hematological cancers. While these unique immunotherapies have improved outcomes for pediatric adult a number disease states, as 'living drugs,' their toxicity profiles, including cytokine release syndrome (CRS) immune cell-associated neurotoxicity (ICANS), differ markedly from conventional cancer therapeutics. At the time article preparation, US Food Drug Administration (FDA)...
Angiosarcoma is an uncommon endothelial malignancy and a highly aggressive soft tissue sarcoma. Due to its infiltrative nature, successful management of localized angiosarcoma often challenging. Systemic chemotherapy used in the metastatic setting occasionally patients with high-risk disease neoadjuvant or adjuvant settings. However, responses tend be short-lived most succumb disease. Novel therapies are needed for angiosarcomas.We performed retrospective analysis locally advanced...
Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched donor, with significant disparity across ethnic groups. We hypothesized that HCT a mismatched (MMUD) post-transplant cyclophosphamide (PTCy), novel strategy successful in overcoming genetic related donors, would be feasible and...
T cell-mediated hyperinflammatory responses, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), are now well-established toxicities of chimeric antigen receptor (CAR) cell therapy. As the field CAR cells advances, however, there is increasing recognition that hemophagocytic lymphohistiocytosis (HLH)-like following infusion occurring broadly across patient populations constructs. Importantly, these HLH-like often not directly associated with CRS...
Abstract We have shown that KRAS–TP53 genomic coalteration is associated with immune-excluded microenvironments, chemoresistance, and poor survival in pancreatic ductal adenocarcinoma (PDAC) patients. By treating cooperativity as a model for high-risk biology, we now identify cell-autonomous Cxcl1 key mediator of spatial T-cell restriction via interactions CXCR2+ neutrophilic myeloid-derived suppressor cells human PDAC using imaging mass cytometry. Silencing cell-intrinsic...
The understanding of human thymic function and evaluation its contribution to T cell homeostasis are matters great importance. Here we report the development a novel assay quantitate frequency diversity recent emigrants (RTEs) in peripheral blood humans. Such cells were defined by presence receptor (TCR) rearrangement deletion circles (DCs), episomal byproducts TCR-β V(D)J rearrangement. DCs detected thymus, cord blood, adult blood. In adults aged 22 76 years, their was highest CD4+CD45RA+...
ABSTRACT Gliotoxin was measured in the lungs (mean, 3,976 ± 1,662 ng/g of tissue) and sera 36.5 30.28 ng/ml) mice with experimentally induced invasive aspergillosis (IA), levels decreased antifungal therapy. could also be detected cancer patients documented (proven or probable) IA.
Abstract On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland ), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for treatment children young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era personalized cancer immunotherapy, multiple challenges are present ranging from implementation CAR-T program to safe delivery drug, long-term...
On August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for treatment children young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era personalized cancer immunotherapy, multiple challenges are present, ranging from implementation CAR-T program to safe delivery drug, long-term toxicity monitoring,...